Anixa Biosciences Inc (NQ: ANIX )

3.210 -0.150 (-4.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 78,607
Open 3.360
Bid (Size) 3.040 (1)
Ask (Size) 3.500 (40)
Prev. Close 3.360
Today's Range 3.140 - 3.431
52wk Range 2.145 - 5.130
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
FDA Approves Anixa Biosciences' Ovarian Cancer CAR-T Therapy for Individual Patient Trial. Moffit Cancer Center receives approval for a second dose in an ongoing Phase I trial showing early promising... 
Via Benzinga
Exposures Product Safety

Performance

YTD
-18.32%
-18.32%
1 Month
+3.55%
+3.55%
3 Month
+20.22%
+20.22%
6 Month
-0.62%
-0.62%
1 Year
-5.31%
-5.31%

More News

Read More
EXCLUSIVE: Anixa Biosciences Finds Stock Undervalued, Launches $5M Stock Buyback Program
Via Benzinga
ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024
Via InvestorPlace
7 Penny Biotech Stocks to Triple Your Investment
Via InvestorPlace
Recap: Anixa Biosciences Q1 Earnings
Via Benzinga
6 Analysts Have This to Say About Anixa Biosciences
Via Benzinga
The Latest Analyst Ratings for Anixa Biosciences
Via Benzinga
Expert Ratings for Anixa Biosciences
Via Benzinga
Anixa Biosciences, Inc. (NASDAQ: ANIX) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
Via AB Newswire
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Via ACCESSWIRE
Anixa Biosciences, A New Type Of Biotech Company: Could It Disrupt The Cancer Landscape?
Via Benzinga
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Via InvestorPlace
Anixa Biosciences Reveals Updated Data From Breast Cancer Vaccine Trial, Says 'Exceeded Expectations'
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
The 3 Most Undervalued Cheap Stocks to Buy in September 2023
Via InvestorPlace
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via ACCESSWIRE
Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
Via Benzinga
Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Appreciating The Passing Of A Titan & Incorporating Alternative Data Signals
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 23, 2022
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.